Copyright: ©Author(s) 2026.
World J Gastroenterol. May 7, 2026; 32(17): 118502
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.118502
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.118502
| Ref. | Cohort/samples | Targets | Methodology | Key findings |
| Casey et al[71] | 59 GISTs (multi-institutional) + blood/saliva | SDHC promoter | Bisulfite sequencing | Epimutation found in approximately 94% of SDHx-WT cases, including Carney triad; mosaicism in peripheral tissues supports post-zygotic origin |
| Janeway et al[74] | Pediatric and WT GIST (approximately 100) | SDH subunits (SDHB, SDHC epimutations) | IHC + genetic/epigenetic testing | Established SDH-deficient GIST in children/WT adults; SDHB loss by IHC plus SDHC methylation testing defines subset |
| Haller et al[75] | Carney triad GISTs | SDHC promoter | Methylation assays | Recurrent SDHC hypermethylation identified as defining event in Carney triad, absent in Carney-Stratakis |
| Angelini et al[76] | 63 tumors (KIT/PDGFRA-mutant vs SDH-deficient) | Genome-wide | 450K arrays | C promoter hypermethylation represents a characteristic alteration in Carney triad but is not detected in Carney-Stratakis |
| Killian et al[70] | SDH-deficient vs syndromic GIST | Genome-wide | 450K arrays | SDH-deficient GISTs characterized by a hypermethylator profile, with succinate accumulation blocking TET enzyme activity |
| Miettinen et al[72] | 66/756 gastric GIST SDH-deficient | SDH status | IHC + molecular | Defined clinicopathologic spectrum of SDH-deficient GIST; IHC loss of SDHB as front-line marker |
| Saito et al[77] | 35 GISTs | CpG island panel (p15, p16, p73, MGMT, hMLH1, MINT1/2/31) | MSP | 94% tumors showed aberrant methylation; proposed CIMP-like category in GIST |
| Giger et al[78] | Plasma/tissue paired samples | SEPT9 (plasma methylation) | ddPCR | Circulating methylated SEPT9 showed feasibility as a liquid biopsy biomarker (AUC: 0.74-0.79) |
- Citation: Papadakos SP, Mandrakis G, Siakavellas SI, Memos N, Gakiopoulou H, Schizas D, Theocharis S. Epigenetic landscape of gastrointestinal stromal tumors: Mechanistic insights and therapeutic opportunities. World J Gastroenterol 2026; 32(17): 118502
- URL: https://www.wjgnet.com/1007-9327/full/v32/i17/118502.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i17.118502